Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

January 18, 2013

Primary Completion Date

June 24, 2014

Study Completion Date

May 14, 2021

Conditions
Melanoma
Interventions
BIOLOGICAL

BMS-936558 (Nivolumab)

BIOLOGICAL

Placebo matching BMS-936558 (Nivolumab)

DRUG

Dacarbazine

DRUG

Placebo matching Dacarbazine

Trial Locations (75)

1121

Fundacion Cidea, Buenos Aires

2050

Local Institution, Camperdown

2060

Local Institution - 0006, North Sydney

2145

Local Institution, Westmead

2450

Coffs Harbour Health Campus, Coffs Harbour

2730

Herlev Hospital, Herlev

3144

Cabrini Hospital, Malvern

4102

Princess Alexandra Hospital, Woolloongabba

4120

Greenslopes Private Hospital, Greenslopes

4215

Local Institution, Southport

5000

Instituto Oncologico De Cordoba, Córdoba

Royal Adelaide Hospital, Adelaide

Odense University Hospital, Odense

8000

Aarhus Universitetshospital, Aarhus

11527

Laiko Hospital, Athens

14080

Local Institution, Tlalpan

16132

Local Institution, Genova

18547

Metropolitan Hospital, Neo Faliro

20014

Local Institution, Donostia / San Sebastian

20133

Local Institution, Milan

20141

Local Institution, Milan

24105

Local Institution, Kiel

24127

Local Institution, Bergamo

28033

Local Institution, Madrid

28034

Local Institution, Madrid

33075

Hopital Saint Andre, Bordeaux

34295

Hopital St Eloi, Montpellier

34362

Local Institution, Haifa

35128

Local Institution, Padua

37000

Local Institution, Leon, Guanajato

37075

Local Institution, Göttingen

38043

Chu Grenoble - Hopital Albert Michallon, Grenoble

39120

Local Institution, Magdeburg

41009

Local Institution, Seville

45122

Local Institution, Essen

45659

Local Institution, Recklinghausen

46014

Local Institution, Valencia

47014

Local Institution, Meldola (fc)

50937

Local Institution, Cologne

52621

Local Institution, Tel Litwinsky

53100

Local Institution, Siena

55131

Local Institution, Mainz

58240

Local Institution, Morelia

59037

Chru De Lille - Hopital Claude Huriez, Lille

69120

Local Institution, Heidelberg

70124

Local Institution, Bari

72076

Local Institution, Tübingen

75010

Hopital Saint Louis, Paris

80131

Local Institution, Napoli

90419

Local Institution, Nuremberg

91120

Local Institution, Jerusalem

94805

Local Institution - 0013, Villejuif

97080

Local Institution, Würzburg

7630370

Local Institution, Santiago

C1426ANZ

Instituto Medico Especialazado Alexander Fleming, Buenos Aires

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E6

Local Institution - 0039, Vancouver

B3H 2Y9

Qe Ii Health Science Centre, Halfax

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H4A 3J1

Local Institution - 0040, Montreal

Unknown

Local Institution, Viña del Mar

Local Institution, Santiago

00290

Local Institution - 0035, Helsinki

07548

Local Institution, Gera

00144

Local Institution, Roma

03310

Local Institution, Mexico City

0379

Local Institution, Oslo

80-219

Local Institution, Gdansk

93-513

Local Institution, Lodz

02-781

Local Institution, Warsaw

08036

Local Institution - 0056, Barcelona

413 45

Local Institution, Gothenberg

221 85

Local Institution, Lund

901 85

Local Institution, Umeå

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01721772 - Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | Biotech Hunter | Biotech Hunter